Breast Cancer

Methods in Molecular Biology

Volumn 727, Issue , 2011, Pages 141-170

  Czernin, Johannes ^a   Benz, Matthias R ^a   Allen Auerbach, Martin S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; FDG; FLT; PET; PET CT; Staging; Treatment monitoring

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE; BREAST; BREAST TUMOR; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

BONE AND BONES; BREAST; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79956330598     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-062-1_9     Document Type: Chapter

References (113)

1. Berry, D., Cronin, K., Plevritis, S., Fryback, D., Clarke, L., Zelen, M., et al. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353, 1784–92.
2. Jemal, A., Clegg, L.X., Ward, E., et al. (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 10(1), 3–27.
3. Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancert that overexpresses HER2 N Engl J Med 344(11), 783–92.
4. Czernin, J., Allen-Auerbach, M., Schelbert, H.R. (2007) Improvements in cancer staging with PET-CT: literature-based evidence as of September 2006 J Nucl Med 48(1), 78S-88S.
5. Phelps, M., Hoffmann, E., Mullani, N., TerPogossian, M. (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography J Nuc Med 16, 210–4.
6. Czernin, J., Phelps, M.E. (2002) Positron emission tomography scanning: current and future applications Ann Rev Med 53, 89–112.
7. Beyer, T., Townsend, D., Brun, T., Kinahan, P., Charron, M., Roddy, R., et al. (2004) A combined PET-CT scanner for clinical oncology J Nuc Med 41, 1369–79.
8. Rosenberg, R., Hunt, W., Williamson, M., Gilliland, F., Wiest, P., Kelsey, C., et al. (1998) Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico Radiology 209, 511–8.
9. Mandelson, M., Oestreicher, N., Porter, P., White, D., Finder, C., Taplin, S., et al. (2000) Breast density as a predictor of mammographic detection: Comparison of interval-and screen-detected cancers J Natl Cancer Inst 92, 1081–7.
10. Pisano, E., Gatsonis, C., Hendrick, R., Yaffe, M., Baum, J., Acharyya, S., et al. (2005) Diagnostic accuracy of digital versus film mammography for breast cancer screening N Engl J Med 353, 1773–83.
11. Laya, M., Larson, E., Taplin, S., White, E. (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography J Natl Cancer Inst 88, 643–9.
12. Wahl, R., Helvie, M., Chang, A., Andersson, I. (1994) Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET J Nucl Med 3, 872–5.
13. Bird, R., Wallace, T., Yankaskas, B. (1992) Analysis of cancers missed at screening mammography Radiology 184, 613–7.
14. Orel, S., Kay, N., Reynolds, C., Sullivan, D. (1999) BI-RADS categorization as a predictor of malignancy Radiology 211(3), 845–50.
15. Wright, C., Mueller, C. (1995) Screening mammography and public health policy: the need for perspective Lancet 346, 29–32.
16. Hall, J., Lee, M., Newman, B., Morrow, J., Anderson, L., Huey, B., et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21 Science 250, 1684–9.
17. Warner, E., Plewes, D.B., Hill, K.A., Causer, P.A., Zubovits, J.T., Jong, R.A., et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination JAMA 292(1), 1317–25.
18. Kriege, M., Brekelmans, C.T.M., Boetes, C., Besnard, P.E., Zonderland, H.M., Obdeijn, I.M., et al. (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition N Engl J Med 35(15), 427–37.
19. Riedl, C.C., Ponhold, L., Flory, D., Weber, M., Kroiss, R., Wagner, T., et al. (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, pre-invasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer Clin Cancer Res 13(20), 6144–52.
20. Warburg, O., Posener, K., Negelein, E., VIII. (1924) The metabolism of cancer cells Biochem Zeitschr 152, 129–69.
21. Robey, I., Stephen, R., Brown, K., Baggett, B., Gatenby, R., Gillies, R. (2008) Regulation of the Warburg effect in early-passage breast cancer cells Neoplasia 10, 745–56.
22. Hoffman, E.J., Huang, S.C., Phelps, M.E. (1979) Quantitation in positron emission computed tomography J Comput Assist Tomogr 3, 299–308.
23. Buck, A., Schirrmeister, H., Kühn, T., Shen, C., Kalker, T., Kotzerke, J., et al. (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters Eur J Nucl Med Mol Imaging 29(10), 1317–23.
24. Avril, N., Rosé, C., Schelling, M., Dose, J., Kuhn, W., Bense, S., et al. (2005) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18, 3495–502.
25. Dehdashti, F., Mortimer, J.E., Siegel, B.A., Griffeth, L.K., Bonasera, T.J., Fusselman, M.J., et al. (1995) Positron Tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays J Nucl Med 36(10), 1766–74.
26. Bos, R., van der Hoeven, J.J.M., van der Wall, E., van der Groep, P., van Diest, P.J., Comans, E.F.I., et al. (2002) Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20(2), 379–87.
27. Avril, N., Menzel, M., Dose, J., Schelling, M., Weber, W., Janicke, F., et al. (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis J Nucl Med 42(1), 9–16.
28. Oshida, M., Uno, K., Suzuki, M., Nagashima, T., Hashimoto, H., Yagata, H., et al. (1998) Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]D-glucose Cancer 11, 2227–34.
29. Mankoff, D.A., Dunnwald, L.K., Gralow, J.R., Ellis, G.K., Schubert, E.K., Tseng, J., et al. (2003) Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy J Nucl Med 44(11), 1806–14.
30. Schoder, H., Gonen, M. (2007) Screening for cancer with PET and PET-CT: potential and limitations J Nucl Med 48(1), 4S-18S.
31. Vranjesevic, D., Schiepers, C., Silverman, D.H., Quon, A., Villalpando, J., Dahlbom, M., et al. (2003) Relationship between 18FFDG uptake and breast density in women with normal breast tissue J Nucl Med 44(8), 1238–42.
32. Kumar, R., Chauhan, A., Zhuang, H., Chandra, P., Schnall, M., Alavi, A. (2006) Standardized uptake values of normal breast tissue with 2-Deoxy-2-[F-18]Fluoro-Dglucose positron emission tomography: variations with age, breast density, and menopausal status Mol Imaging Biol 8(6), 355–62.
33. Kubota, K., Matsuzawa, T., Amemiya, A., Kondo, M., Fujiwara, T., Watanuki, S., et al. (1989) Imaging of breast cancer with [f18] Fluorodeoxyglucose and positron emission tomography J Comput Asst Tomogr 13, 1097.
34. Bassa, P., Kim, E.E., Wong, F.C., Korkmaz, M., Yang, D., et al. (1996) Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer J Nucl Med 37, 931–8.
35. Rostom, A.Y., Powe, J., Kandil, A., Ezzat, A., Bakheet, S., El-Khwsky, F., et al. (1999) Positron emission tomography in breast cancer: a clinicopathological correlation of results Br J Radiol 72, 1064–8.
36. Utech, C., Young, C., Winter, P. (1996) Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry Eur J Nucl Med 23, 1588–93.
37. Noh, D., Yun, I., Kim, J., Kang, H., Lee, D., Chung, J., et al. (1998) Diagnostic value of positron emission tomography for detecting breast cancer World J Surg 22, 223–8.
38. Schirrmeister, H., Kühn, T., Guhlman, A., Santjohanser, C., Hörster, T., Nüssle, K., et al. (2001) Fluorine-18 2-deoxy-2-fluoroD-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures Eur J Nuc Med 28, 351–8.
39. Tse, N., Hoh, C., Hawkins, R., Zinner, M., Dahlbom, M., Choi, Y., et al. (1992) The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease Ann Surg 16(1), 27–34.
40. Nieweg, O., Kim, E., Wong, W., Broussard, W., Singletary, E., Hortobagyi, G., et al. (1993) Positron emsission tomography with Fluorine-18-deoxyglucose in the detection and staging of breast cancer Cancer 71, 3920–5.
41. Adler, L.P., Crowe, J.P., al-Kaisi, N.K., Sunshine, J.L. (1993) Evaluation of breast masses and axillary lymph nodes with [F-18] 2 deoxy-2-fluoro-D-glucose PET Radiology 187, 743–50.
42. Avril, N., Dose, J., Jänicke, F., Bense, S., Ziegler, S., Laubenbacher, C., et al. (1996) Metabolic characterization of breast tumors with positron emission tomography using F-18 Fluorodeoxyglucose J Clin Oncol 14, 1848–57.
43. Crippa, F., Seregeni, E., Agresti, R., Chiesa, C., Pascali, C., Bogni, A., et al. (1996) Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation Eur J Nuc Med 25, 1429–34.
44. Noh, D., Yun, I., Kang, H., Kim, Y., Kim, J., Chung, J., et al. (1999) Detection of cancer in augmented breasts by positron emission tomography Eur J Surg 165, 847–51.
45. Avril, N., Rose, C.A., Schelling, M., Dose, J., Kuhn, W., Bense, S., et al. (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18(20), 3495–502.
46. Bleckmann, C., Dose, J., Bohuslavizki, K., Buchert, R., Klutman, S., Mester, J., et al. (1999) Effect of attenuation correction on lesion detectability in FDG PET of breast cancer J Nuc Med 40, 2021–4.
47. Yutani, K., Hojo, S., Tatsumi, M., Shiba, E., Noguchi, S., Nishimura, T. (1999) Correlation of F-18-FDG and Tc-99m-MIBI uptake with proliferative activity in breast cancer J Nucl Med 40(5), 16P–17P.
48. Boerner, A., Weckesser, M., Herzog, H., Schmitz, T., Audretsch, W., Nitz, U., et al. (1999) Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer Eur J Nucl Med 26, 226–30.
49. Mavi, A., Urhan, M., Yu, J.Q., Zhuang, H., Houseni, M., Cermik, T.F., et al. (2006) Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes J Nucl Med 47(9), 1440–6.
50. Doshi, N., Shao, Y., Silverman, R., Cherry, S. (2000) Design and evaluation of an LSO PET detector for breast cancer imaging Med Phys 27, 1535–43.
51. Raylman, R., Majewski, S., Smith, M., Proffitt, J., Hammond, W., Srinivasan, A., et al. (2008) The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements Phys Med Biol 53, 637–53.
52. Tafra, L., Cheng, Z., Uddo, J., Lobrano, M.B., Stein, W., Berg, W.A., et al. (2005) Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer Am J Surg 190(4), 628–32.
53. Berg, W.A., Weinberg, I.N., Narayanan, D., et al. (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer Breast J 12(4), 309–23.
54. Berriolo-Riedinger, A., Touzery, C., Riedinger, J-M., Toubeau, M., Coudert, B., Arnould, L., et al. (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging 34(12), 1915–24.
55. Krag, D., Weaver, D., Ashikaga, T., Moffat, F., Klimberg, V.S., Shriver, C., et al. (1998) The sentinel node in breast cancer--a multicenter validation study N Engl J Med 339(14), 941–6.
56. Adler, L., Faulhaber, P., Schnur, K., Al-Kasai, N., Shenk, R. (1997) Axillary lymph node metastases: screening with [F-18]2 deoxy-2-Dglucose (FDG) PET Radiology 203, 323–7.
57. Crippa, F., Agresti, R., Donne V.D., Pascali, C., Bogni, A., Chiesa, C., et al. (1997) The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the pre-operative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan Tumori 83, 542–3.
58. Crippa, F., Agresti, R., Seregni, E., Greco, M., Pascali, C., Bogni, A., et al. (1998) Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer J Nucl Med 39, 4–8.
59. Smith, I., Ogston, K., Whitford, P., Smith, F., Sharp, P., Norton, M., et al. (1998) Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fliuoro-2deoxy-D-glucose Ann Surg 228, 220–7.
60. Yutani, K., Shiba, E., Tatsumi, M., Uehara, T., Taguchi, T., Takai, S-I., et al. (2000) Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis J Comput Assist Tomogr 24, 274–80.
61. Wahl, R.L., Siegel, B.A., Coleman, R.E., Gatsonis, C.G. (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a Report of the Staging Breast Cancer With PET Study Group J Clin Oncol 22(2), 277–85.
62. Fuster, D., Duch, J., Paredes, P., Velasco, M., Munoz, M., Santamaria, G., et al. (2008) Preoperative staging of large primary breast cancer with [18F]Fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures JCO 17, 1496.
63. Donegan, W. (1977) The influence of untreated internal mammary metastases upon the course of mammary cancer Cancer 39, 533–8.
64. Eubank, W.B., Mankoff, D.A., Takasugi, J., Vesselle, H., Eary, J.F., Shanley, T.J., et al. (2001) 18-Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer J Clin Oncol 19(15), 3516–23.
65. Tran, A., Pio, B.S., Khatibi, B., Czernin, J., Phelps, M.E., Silverman, D.H.S. (2005) 18FFDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome J Nucl Med 45(9), 1455–9.
66. Carey, L.A., Metzger, R., Dees, E.C., Collichio, F., Sartor, C.I., Ollila, D.W., et al. (2005) American Joint Committee on Cancer TumorNode-Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome J Natl Cancer Inst 97(15), 1137–42.
67. Mahner, S., Schirrmacher, S., Brenner, W., Jenicke, L., Habermann, C.R., Avril, N., et al. (2008) Comparison between positron emission tomography using 2-[fluorine-18] fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer Ann Oncol 19(7), 1249–54.
68. Fueger, B., Weber, W., Quon, A., Crawford, T., Allen-Auerbach, M., Halpern, B., et al. (2005) Performance of 2-Deoxy-2-[F-18] fluoro-D-glucose positron emission tomography and integrated PET-CT in restaged breast cancer patients Mol Imaging Biol 7, 369–76.
69. Radan, L., Ben-Haim, S., Bar-Shalom, R., Guralnik, L., Israel, O. (2006) The role of FDG-PET-CT in suspected recurrence of breast cancer Cancer 107(11), 2545–51.
70. Veit-Haibach, P., Antoch, G., Beyer, T., Stergar, H., Schleucher, R., Hauth, E.A.M., et al. (2007) FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy Br J Radiol 80(955), 508–15.
71. Heusner, T.A., Kuemmel, S., Umutlu, L., Koeninger, A., Freudenberg, L.S., Hauth, E.A.M., et al. (2008) Breast cancer staging in a single session: whole-body PET-CT mammography J Nucl Med 49(8), 1215–22.
72. Cook, G., Fogelman, I. (1999) Skeletal metastases from breast cancer: imaging with nuclear medicine Semin Nucl Med 29, 69–79.
73. Cook, G.J.R. (2003) Oncological molecular imaging: nuclear medicine techniques Br J Radiol, 76(2), S152–8.
74. Puglisi, F., Follador, A., Minisini, A.M., Cardellino, G.G., Russo, S., Andreetta, C., et al. (2005) Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications Ann Oncol 16(2), 263–6.
75. Kasem, A.R., Desai, A., Daniell, S., Sinha, P. (2006) Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer Breast J 12(6), 544–8.
76. Cook, G.J., Houston, S., Rubens, R., Maisey, M.N., Fogelman, I. (1998) Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions J Clin Oncol 16(10), 3375–9.
77. Specht, J., Tam, S., Kurland, B., Gralow, J., Livingston, R., Linden, H., et al. (2007) Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP) Breast Cancer Res Treat 105(1), 87–94.
78. Du, Y., Cullum, I., Illidge, T.M., Ell, P.J. (2007) Fusion of metabolic function and morphology: sequential [18F]Fluorod eoxyglucose positron-emission tomography/ computed tomography studies yield new insights into the natural history of bone metastases in breast cancer J Clin Oncol 25(23), 3440–7.
79. Blau, M., Nagler, W., Bender, M. (1962) Fluorine-18: a new isotope for bone scanning J Nucl Med 3, 332–4.
80. Schirrmeister, H., Guhlmann, A., Kotzerke, J., Santjohanser, C., Kuhn, T., Kreienberg, R., et al. (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography J Clin Oncol 17(8), 2381–9.
81. Even-Sapir, E., Metser, U., Flusser, G., Zuriel, L., Kollender, Y., Lerman, H., et al. (2004) Assessment of malignant skeletal disease: initial experience with 18F-Fluoride PET-CT and comparison between 18F-Fluoride PET and 18F-Fluoride PET-CT J Nucl Med 45(2), 272–8.
82. Lordick, F., Ott, K., Krause, B-J, Weber, W.A., Becker, K., Stein, H.J., et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial Lancet Oncol 8(9), 797–805.
83. Weber, W.A., Figlin, R. (2007) Monitoring cancer treatment with PET-CT: does it make a difference J Nucl Med 48(1), 36S-44S.
84. Minn, H., Soini, I. (1989) [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer Eur J Nucl Med 15, 61–6.
85. Wahl, R.L., Zasadny, K., Helvie, M., Hutchins, G.D., Weber, B., Cody, R. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11(11), 2101–11.
86. Bruce, D., Evans, N., Heys, S., Needham, G., Ben Younes, H., Mikecz, P., et al. (1995) Positron emission tomography: 2-deoxy-2[18F]-fluoro-D-glucose uptake in locally advanced breast cancers Eur J Surg Oncol 21, 280–3.
87. Dehdashti, F., Flanagan, F.L., Mortimer, J., Katzenellenbogen, J., Welch, M., Siegel, B.A. (1998) Positron emission tomographic assessment of “metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy Eur J Nuc Med 26, 51–6.
88. Schelling, M., Avril, N., Nahrig, J., Kuhn, W., Romer, W., Sattler, D., et al. (2000) Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18(8), 1689–95.
89. Smith, I.C., Welch, A.E., Hutcheon, A.W., Miller, I.D., Payne, S., Chilcott, F., et al. (2000) Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18(8), 1676–88.
90. Wolmark, N., Wang, J., Mamounas, E., Bryant, J., Fisher, B. (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Institute Monogr 30, 96–102.
91. Rousseau, C., Devillers, A., Sagan, C., Ferrer, L., Bridji, B., Campion, L., et al. (2006) Monitoring of early response to neoadjuvant chemotherapy in Stage II and III breast cancer by [18F]Fluorodeoxyglucose positron emission tomography J Clin Oncol 24(34), 5366–72.
92. Dunnwald, L.K., Gralow, J.R., Ellis, G.K., Livingston, R.B., Linden, H.M., Specht, J.M., et al. (2008) Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer J Clin Oncol 26(27), 4449–57.
93. Dose Schwarz, J., Bader, M., Jenicke, L., Hemminger, G., Janicke, F., Avril, N. (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 46(7), 1144–50.
94. Couturier, O., Jerusalem, G., N’Guyen, J-M, Hustinx, R. (2006) Sequential positron emission tomography using [18F] Fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer Clin Cancer Res 12(21), 6437–43.
95. Cachin, F., Prince, H.M., Hogg, A., Ware, R.E., Hicks, R.J. (2006) Powerful prognostic stratification By [18F]Fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy J Clin Oncol 24(19), 3026–31.
96. Yap C, Valk P, Ariannejad M, Seltzer M, Phelps M, Gambhir S et al. (2002) FDGPET influences the clinical management of lymphoma patients J Nucl Med 41(5):70P
97. Hillner, B.E., Siegel, B.A., Liu, D., Shields, A.F., Gareen, I.F., Hanna, L., et al. (2008) Impact of positron emission tomography/ computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry J Clin Oncol 26(13), 2155–61.
98. Shields, A.F., Grierson, J.R., Dohmen, B.M., Machulla, H.J., Stayanoff, J.C., Lawhorn-Crews, J.M., et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4(11):1334–6.
99. Bading, J.R., Shields, A.F. (2008) Imaging of cell proliferation: status and prospects J Nucl Med 49(2), 64S–80S.
100. Toyohara, J., Waki, A., Takamatsu, S., Yonekura, Y., Magata, Y., Fujibayashi, Y. (2002) Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines Nucl Med Biol 29(3): 281–7.
101. Smyczek-Gargya, B., Fersis, N., Dittmann, H., Vogel, U., Reischl, G., Machulla, H-J, et al. (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study Eur J Nucl Med Mol Imaging 31(5), 720–4.
102. Kenny, L.M., Vigushin, D.M., Al-Nahhas, A., Osman, S., Luthra, S.K., Shousha, S., et al. (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F] Fluorothymidine-positron emission tomography imaging: evaluation of analytical methods Cancer Res 65(21), 10104–12.
103. Pio, B., Park, C., Pietras, R., Hsueh, W-A, Satyamurthy, N., Pegram, M., et al. (2006) Usefulness of 3¢-[F-18]Fluoro-3¢deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8(1), 36–42.
104. Peterson, L.M., Mankoff, D.A., Lawton, T., Yagle, K., Schubert, E.K., Stekhova, S., et al. (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-Fluoroestradiol J Nucl Med 49(3), 367–74.
105. Linden, H.M., Stekhova, S.A., Link, J.M., Gralow, J.R., Livingston, R.B., Ellis, G.K., et al. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24(18), 2793–9.
106. Schneider, B., Sledge, G. (2007) Drug Insight: VEGF as a therapeutic target for breast cancer Nat Clin Pract Oncol 4, 181–9.
107. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh,M.A.,Marcom, P.K., Fehrenbacher, L., et al. (2005) Randomized Phase III trial of Capecitabine compared with Bevacizumab plus Capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23(4), 792–9.
108. Kenny, L.M., Coombes, R.C., Oulie, I., Contractor, K.B., Miller, M., Spinks, T.J., et al. (2008) Phase I trial of the positronemitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J Nucl Med 49(6), 879–86.
109. Smith-Jones, P.M., Solit, D.B., Akhurst, T., Afroze, F., Rosen, N., Larson, S.M. (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors Nat Biotechnol 22, 701–6.
110. Smith-Jones, P.M., Solit, D.B., Afroze, F., Rosen, N., Larson, S.M. (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET J Nucl Med 47(5), 793–6.
111. Weber, W., Czernin, J., Phelps, M., Herschman, H. (2008) Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs Nat Clin Pract Oncol 5, 44–54.
112. Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Sarbia, M., et al. (2005) Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [(18) F]Galacto-RGD. PLoS Med 2(3), e70.
113. Rajendran, J.G., Mankoff, D.A., O’Sullivan, F., Peterson, L.M., Schwartz, D.L., Conrad, E.U., et al. (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]Fluo-romisonidazole and [18F] Fluorodeoxyglucose positron emission tomography imaging Clin Cancer Res. 10(7), 2245–52.